CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes

Alexander Roberts, Gillian Grafton, Andrew D. Powell, Kristian Brock, Chunlin Chen, Dejian Xie, Jinkun Huang, Shuang Liu, Alison J. Cooper, Catherine A. Brady, Omar Qureshi, Zania Stamataki, David D. Manning, Nicholas A. Moore, Bruce J. Sargent, Peter R. Guzzo, Nicholas M. Barnes*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    10 Citations (SciVal)
    Original languageEnglish
    Pages (from-to)122-134
    Number of pages13
    JournalJournal of Pharmacology and Experimental Therapeutics
    Volume373
    Issue number1
    DOIs
    Publication statusPublished (VoR) - 1 Apr 2020

    Fingerprint

    Dive into the research topics of 'CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes'. Together they form a unique fingerprint.

    Cite this